Cargando…
Naturally occurring compounds as pancreatic cancer therapeutics
Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit f...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226042/ https://www.ncbi.nlm.nih.gov/pubmed/30459936 http://dx.doi.org/10.18632/oncotarget.26234 |
_version_ | 1783369890039595008 |
---|---|
author | Lohse, Ines Wildermuth, Erin Brothers, Shaun P. |
author_facet | Lohse, Ines Wildermuth, Erin Brothers, Shaun P. |
author_sort | Lohse, Ines |
collection | PubMed |
description | Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds. |
format | Online Article Text |
id | pubmed-6226042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-62260422018-11-20 Naturally occurring compounds as pancreatic cancer therapeutics Lohse, Ines Wildermuth, Erin Brothers, Shaun P. Oncotarget Review Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds. Impact Journals LLC 2018-10-23 /pmc/articles/PMC6226042/ /pubmed/30459936 http://dx.doi.org/10.18632/oncotarget.26234 Text en Copyright: © 2018 Lohse et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Lohse, Ines Wildermuth, Erin Brothers, Shaun P. Naturally occurring compounds as pancreatic cancer therapeutics |
title | Naturally occurring compounds as pancreatic cancer therapeutics |
title_full | Naturally occurring compounds as pancreatic cancer therapeutics |
title_fullStr | Naturally occurring compounds as pancreatic cancer therapeutics |
title_full_unstemmed | Naturally occurring compounds as pancreatic cancer therapeutics |
title_short | Naturally occurring compounds as pancreatic cancer therapeutics |
title_sort | naturally occurring compounds as pancreatic cancer therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226042/ https://www.ncbi.nlm.nih.gov/pubmed/30459936 http://dx.doi.org/10.18632/oncotarget.26234 |
work_keys_str_mv | AT lohseines naturallyoccurringcompoundsaspancreaticcancertherapeutics AT wildermutherin naturallyoccurringcompoundsaspancreaticcancertherapeutics AT brothersshaunp naturallyoccurringcompoundsaspancreaticcancertherapeutics |